Content about Zoledronic acid

April 4, 2013

Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

March 5, 2013

Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

Dr. Reddy's announced the launch of injectable zoledronic acid in the 4-mg-per-5-mL strength. The launch followed the Food and Drug Administration's approval of the drug.

The drug is a generic version of Novartis' Zometa. The drug is used to treat cancers that have spread to the bones and multiple myeloma.

CORRECTION: An earlier version of this story misstated the strength of the drug. The story has been corrected.

December 13, 2010

A drug made by Amgen was able to delay certain bone problems in patients with advanced breast cancer better than a competing drug, according to study results presented at the 33rd annual San Antonio Breast Cancer Symposium.

THOUSAND OAKS, Calif. — A drug made by Amgen was able to delay certain bone problems in patients with advanced breast cancer better than a competing drug, according to study results presented at the 33rd annual San Antonio Breast Cancer Symposium.

Amgen said Xgeva (denosumab) was able to delay weakness and fracturing resulting from the cancer spreading to the bones five months longer than Novartis’ Zometa (zoledronic acid).

The Food and Drug Administration approved Xgeva on Nov. 18.

November 18, 2010

The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients...

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.

 

The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.

 

 

May 18, 2010

Amgen has submitted a regulatory approval application to the Food and Drug Administration for a...

March 11, 2010

Analysis by the Food and Drug Administration has yet to establish a link between thigh-bone...

February 8, 2010

An investigational drug made by Amgen for treating prostate cancer that had spread to the...

January 28, 2010

The Food and Drug Administration has given tentative approval to a generic version of a...